FT : Economists sceptical QE can revive eurozone

Economists sceptical QE can revive eurozone

Any effort by the European Central Bank to launch a massive quantitative easing programme this year would fail to revive the eurozone economy, according to economists polled in a Financial Times survey. The FT survey of 32 eurozone economists, mainly working in the financial sector, conducted in mid-December, found most expected the ECB to launch QE in 2015 — catching up with the world’s other main central banks that have all bought large quantities of sovereign debt since the last financial crisis. Twenty-six economists forecast the central bank would start purchasing government bonds this year, while five thought it would not. One did not respond to the question. A stuttering recovery and a worrying drop in inflation have raised fears of another financial crisis in the currency bloc and put pressure on policy makers to cast aside powerful opposition from Germany and begin purchasing sovereign debt. ECB president Mario Draghi last week gave his strongest signal yet that the central bank would extend its asset purchases to include sovereign debt in the next few months. A decision could come as early as the next governing council meeting on January 22. But most of the FT poll’s respondents expected growth and inflation to remain weak even with quantitative easing. "[QE] will help lift inflation expectations and reduce the euro, but [it’s] not a total game changer," said Dario Perkins, economist at Lombard Street Research. Jörg Krämer of Commerzbank said QE would lower the yield on government bonds and "help the finance ministries of highly indebted countries such as Italy, and its banks". But he added that QE would not change low growth and inflation levels and would "only fuel asset prices". While several respondents said government bond-buying was likely to help fight the threat of deflation and lower yields on debt issued by weaker sovereigns, most economists agreed that growth would remain lacklustre unless governments backed the ECB’s efforts. "QE is not a panacea for the euro-area," said Carsten Brzeski of ING DiBa, a bank. He suggested that the biggest impact from any QE would come "if governments were at the same time allowed to start a deficit-financed investment programme. [It’s] doubtful [that] will ever happen in the euro area." Some said a larger package stood more chance of success. "If it is big enough, it will have some effect on the economy, if only to bring the euro down," said Jonathan Loynes of research group Capital Economics. "It’s worth a try." Of the economists who put a number on the size of the purchases, the most popular guess was €500bn, although some put the figure as high as €1tn and others as low as €250bn. Some also expected the ECB to start buying corporate debt alongside sovereign bonds. Eurozone inflation dropped to 0.3 per cent in November, less than a fifth of the ECB’s target of just below 2 per cent. Inflation is likely to have fallen again in December on the back of the sharp drop in oil prices. Mr Draghi and most of the governing council backed a new development in ECB policy in December, saying the expansion of the central bank’s balance sheet from €2tn towards the €3tn mark was now expected. However, six policy makers objected to the December decision, underlining the extent of divisions over quantitative easing. Jens Weidmann, the Bundesbank’s president, was among the dissenters, and while Berlin is not expected publicly to oppose the policy, resistance within Germany remains fierce. Many economists think it is impossible for the ECB to hit the €3tn level by confining its purchases to the assets it buys at the moment: covered bonds and asset-backed securities. "The ECB will purchase sovereign debt in 2015, mostly for want of anything else to buy," said Lorcan Roche Kelly of Agenda Research. Twenty-six respondents to the FT’s poll thought the size of the ECB’s balance sheet would lie somewhere between €2tn and €3tn by the end of 2015. Two thought the ECB would be able to hit €3tn over the next 12 months, while four thought the balance sheet would fall below €2tn. Some respondents thought resistance within the council could affect the programme, with others suggesting the ECB would ensure national central banks bore the risk from buying their governments’ bonds. "The ECB will most probably have to limit sovereign purchases to investment grade sovereigns," said Hetal Mehta of Legal & General Investment Management, an insurer. "The purchases will consist of nationally-weighted sovereign [debt purchases]. I think that [credit] risk will probably [be] decentralised at the national level via some mechanism," said Lucrezia Reichlin, a professor at London Business School and co-founder of data firm NowCasting. Richard Barwell of Royal Bank of Scotland said: "There may be compromises in the design to get as many people on board as possible, but I expect a sufficiently strong signal that the ECB is determined to do what it takes to preserve price stability and that’s what counts in the end." Kit Juckes of Société Générale said buying European Investment Bank bonds to spur investment spending was a "more appealing" way for the ECB to spend its cash. Harald Benink, a professor at Tilburg University, agreed. "Our proposal of buying bonds . . . issued by the EIB is likely to be more acceptable to the Bundesbank since it is violating to a lesser extent monetary financing rules as contained in the [EU] Treaty", he said.

*EURO DROPS TO AS LOW AS $1.1864, WEAKEST SINCE MARCH 2006

Back to 1.1940 now

+------------------------------------------------------------------------------+

BFW 01/04 22:33 *EURO PARES DECLINES TO TRADE AT $1.1938, DOWN 0.6% FROM JAN. 2 BFW 01/04 22:32 *EURO DROPS TO $1.1864, WEAKEST LEVEL SINCE MARCH 2006 BFW 01/04 22:32 *EURO DROPS TO AS LOW AS $1.1864, WEAKEST SINCE MARCH 2006 BN 01/04 22:31 *EURO DROPS TO AS LOW AS $1.1864, WEAKEST SINCE MARCH 2006

+------------------------------------------------------------------------------+

Euro Drops to $1.1864, Weakest Since 2006, on Draghi Comments 2015-01-04 22:36:06.275 GMT

By Benjamin Purvis (Bloomberg) -- EUR/USD falls as much as 1.2%, trades at $1.1944 as of 7:33am Tokyo time, down 0.5% vs Jan. 2. * USD stronger against all G-10 currencies today * AUD/USD reaches new 4 1/2-yr low of 0.8065 as 15-yr Aussie bond yield drops to record 3.005% * “The euro remained firmly out of favor as markets bank on details of upcoming ECB quantitative easing being nailed down as soon as Jan. 22,” ANZ Bank said today in a research note. USD to extend gains as “roadblocks are expected to be few and far between on a journey towards a higher Fed Funds rate.”

For Related News and Information: First Word scrolling panel: {FIRST<GO>} First Word newswire: {NH BFW<GO>}

To contact the reporter on this story: Benjamin Purvis in Sydney at +61-2-9777-8657 or bpurvis@bloomberg.net

To contact the editor responsible for this story: Garfield Reynolds at +61-2-9777-8695 or greynolds1@bloomberg.net

Reuters - Germany's Gabriel says Berlin wants Greece to stay in euro zone

Germany's Gabriel says Berlin wants Greece to stay in euro zone

* German Economy Minister says Greece should stay in euro zone

* Germany says new Greek government must honour obligations

* Der Spiegel: "Grexit" seen likely if Syriza wins power

BERLIN, Jan 4 (Reuters) - The German government wants Greece to stay in the euro zone and there are no contingency plans to the contrary, Vice Chancellor Sigmar Gabriel said on Sunday, responding to a media report that Berlin believes the currency union could cope without Greece.

Gabriel, the Economy Minister and leader of the centre-left Social Democrats (SPD), also told the Hanoversche Allgemeine Zeitung that the euro zone had become more resilient in recent years and could not be "blackmailed".

"The goal of the German government, the European Union and even the government in Athens itself is to keep Greece in the euro zone," Gabriel said in the interview to appear on Monday.

"There were no and there are no other plans to the contrary," he said, and noted the euro zone had become far more stable in recent years.

"That's why we can't be blackmailed and why we expect the Greece government, no matter who leads it, to abide by the agreements made with the EU," he said referring to the Jan. 25 Greek election and possible change of government.

Earlier a spokesman for Chancellor Angela Merkel, Georg Streiter, said the German government expects Greece to stick to the terms of its 240-billion euro EU/IMF bailout agreement.

Streiter declined to comment on a report in Der Spiegel magazine on Saturday that said Berlin had shifted its view and now believed the euro zone would be able to cope with a Greek exit, or "Grexit", if necessary.

Der Spiegel reported that Berlin considers "Grexit" almost unavoidable if the left-wing Syriza opposition party, narrowly ahead in opinion polls, wins Greece's election. Syriza wants to cancel austerity measures and a chunk of Greek debt.

But the report said that both Merkel and Finance Minister Wolfgang Schaeuble now believe the euro zone has implemented enough reforms since the height of its debt crisis in 2012 to make a potential Greek exit manageable.

In addition, the euro zone now has an "effective" bailout fund, the European Stability Mechanism (ESM), another source added. Major banks would be protected by the banking union.

As the euro zone's paymaster, Germany is insisting that Greece must stick to a course of austerity and not backtrack on its bailout commitments - especially as it does not want to open the door for other struggling euro zone members to relax their reform efforts.

Peter Bofinger, on the "wisemen" council of economic advisers to the German government, warned against "Grexit".

"There would be many high risks for the stability of the euro zone with such a step," he told Welt am Sonntag. "It would let a genie out of the bottle that would be hard to control."

WSJ : CEOs Make Bullish Pitch for 2015

CEOs Make Bullish Pitch for 2015
Corporate Leaders Cite Economy, Gasoline Prices and Hiring as Positive for Business

How’s business shaping up for 2015?

We asked the 153 members of The Wall Street Journal CEO Council if they are positive or negative about the year ahead. And they said…

Wait a minute. Is this really as good a barometer as it sounds? CEOs aren’t exactly your average personality type. They are, it turns out, optimism addicts—or at least good at positive spin.

Writing in the Journal of Financial Economics in 2013, a group of Duke University researchers said they studied the traits of more than 1,000 chief executives and classified 80% as “very optimistic”—a percentage significantly higher than what is found in the general population.

True to form, our survey found the corporate leaders overwhelmingly inclined to turn a frown upside down. They are bullish on 2015 and cite a long list of new tailwinds, and a shorter list of headwinds.

“Lower gas prices, higher employment rates and stronger consumer confidence should boost the consumer marketplace,” says Brian Cornell, CEO of Target Corp.

There’s “traction in middle-class incomes,” says Gerry Lopez, CEO of AMC Entertainment Holdings Inc. “Lower energy costs do provide a sense that the gains may be sustainable. For the first time in six-plus years it seems we’re focused on growth, not on sputtering around waiting for some indicator or another.”

“Momentum, even a little, fuels momentum,” adds Eric Elliott, CEO of Prime Therapeutics LLC, a prescription-drug benefit company

And momentum gives business some room to maneuver. “In this environment,” says Yang Yuanqing , CEO of Lenovo Group Ltd. , “we will see innovation thrive, and we will see innovators win.”

That optimism is echoed in other readings of business sentiment. The Institute for Supply Management last month said its survey found manufacturers expecting a 5.6% rise in revenue in 2015. Nonmanufacturing companies, like service firms, expect a 10% jump. The ISM survey also found executives confident that their costs of goods and labor will stay relatively stable.

What’s got our CEOs worried? The usual suspects: ennui in Europe, a restless Russia, turmoil in the Mideast, the slowdown in China and emerging markets, the Japanese dice-roll that is Abenomics (and U.S. monetary policy, for that matter). All this makes for a global market that “will continue to be highly volatile in 2015,” notes Kasper Rorsted, CEO of Henkel AG , the German consumer-products company. Still, he’s positive about the year to come.

This isn’t just a matter of macro trends raising all boats. The CEOs see specific factors helping (and in some cases hurting) their business.

“The proliferation of connected devices and growth in on-demand availability” mean consumers will want more entertainment content, which is good for Time Warner Inc., says CEO Jeff Bewkes .

Donald Jernigan, CEO of Adventist Health System, says the Affordable Care Act is boosting business at his hospital group. Robert Garrett, CEO of Hackensack University Health Network, has at the top of his list of positives: “More people signing up for health-care coverage.” Similarly, John Hammergren , CEO of drug wholesaler McKesson Corp. , says demand is up and he’s “very optimistic about 2015 and beyond.”

Over at the Nasdaq, it is about deals and disruption. And these days there is plenty of both.

“There is a robust pipeline of public companies and private enterprises looking for ways to use technology to create greater efficiencies, reshape industries and compete for talent,” says CEO Bob Greifeld . “This creates a vibrant ecosystem for IPOs and private marketplaces, and we operate both.”

But, of course, one person’s meat is another’s poison. The recent drop in commodity prices may boost profits at manufacturers. It can be a problem, however, for companies like Aurizon Holdings Ltd. , the big Australian rail-freight operator, which hauls those commodities (think iron ore). CEO Lance Hockridge says he’s “cautiously optimistic” about 2015. Asia isn’t going to stop urbanizing or industrializing anytime soon, he notes. He says he is confident about long-term demand.

And for Massachusetts Mutual Life Insurance Co., 2015 looks like “a mixed bag,” says Roger Crandall, CEO. Wall Street may be effervescent, but Middle America isn’t feeling the love. Underemployment is still an issue. “It doesn’t feel like a full recovery,” he says. “Life-insurance ownership is at a 50-year low.”

That said, there’s also the good news. MassMutual is outpacing the rate of growth of its industry, says Mr. Crandall. “We expect that to continue in 2015,” he says.

CEO: Chief Executive of Optimism.

FT : Permanent capital: Perpetual cash machines

Permanent capital: Perpetual cash machines

William "Bill" Ackman, founder and chief executive officer of Pershing Square Capital Management LP, speaks during an event in New York, U.S., on Tuesday, July 22, 2014. Herbalife Ltd. shares fell the most in three months yesterday after billionaire Ackman vowed to show Enron Corp.-like fraud at the seller of supplements and weight-loss shakes. Photographer: Jin Lee/Bloomberg *** Local Caption *** Bill Ackman©Bloomberg
Bill Ackman, founder and CEO of Pershing Square hedge fund
In 2009, Bill Ackman surveyed the wreckage of the US property market and spotted a golden opportunity. General Growth Properties, owner of shopping malls in 40 American states, was teetering on the verge of bankruptcy — and Mr Ackman, founder of the Pershing Square hedge fund, sensed it was time to buy.
There was just one problem: his own investors. Spooked by the financial and economic crisis spreading around them, many Pershing clients were asking for their money back. To cope with the flood of redemption requests, Mr Ackman had to keep almost half his fund in cash — money that he wanted to put to work in companies like General Growth.

Today, General Growth is worth 140 times its value in 2009. Pershing Square is thought to have made about $3.5bn from its investment in General Growth, but Mr Ackman still rues not being able to invest more in the company.
“I had one hand tied behind my back,” Mr Ackman recalls. “In 2009, we wanted to go on the offensive. But even though we were up a lot that year I still felt like we missed out. Because of the possibility of massive redemptions we had to hold too much cash.”
Hedge fund and private equity managers have always been subject to the whims of their investors or the rules of their funds. After all, the money belongs to their clients. But, for the managers, few things are more galling than having to pass on a “sure thing” because they have to give the money back, as Mr Ackman was forced to do.
Now many of the world’s savviest hedge fund and private equity managers think they have found a way round the problem. Instead of traditional funds that allow investors regular opportunities to redeem their money, or buyout funds that wind up after 10 years, they are looking to raise money for vehicles that bring cash in that can be invested in perpetuity. In the industry parlance, this is known as “permanent capital” and is seen as a new holy grail.
Whether these are stock market listed funds or acquisition vehicles that raise money in public share offerings, or reinsurance companies that bring in premiums to invest, they have a few things in common: fat fees and an end to the need to plead with potential investors to write cheques every few years.
Private equity bosses, complaining about a shortage of cheap companies to buy, are staring at years of lower returns. And with hedge funds having had their fourth consecutive year of sub-10 per cent growth, pension funds such as Calpers are reconsidering their investments. Pressure on fees is intensifying and permanent capital raised now could lock in arrangements that may in the future look quite generous.
While it is too early to say how many of these vehicles will justify the fees they pay to their managers, the quest for permanent capital is already changing the alternative investment management industry. Hedge fund managers and private equity firms are getting larger, more diverse and more institutional, becoming more like traditional fund management groups where gathering assets may be prized ahead of generating stellar returns.
The inspiration for many alternative managers is Berkshire Hathaway, the listed investment vehicle of Warren Buffett, who for 50 years has been able to invest the profits from his businesses and the premiums from his insurance operations without investors pressuring him to return cash to them. The result is that Berkshire is the fourth largest company on the US stock market.
“Everyone is suffering from Warren Buffett envy,” says the head of a private equity firm in New York. Berkshire had the money for rescue loans to Goldman Sachs in 2008 and Bank of America in 2011, moments of great fear in the markets when everyone except the US government seemed to be fleeing. Berkshire has made profits of more than $12bn to date on those deals.
Mr Ackman has been mulling the need for permanent capital since the crisis and, by giving discounts on fees and other incentives, has lured $6.7bn into a closed-end fund called Pershing Square Holdings. The vehicle was listed on the Euronext stock market in October, in what was the largest initial public offering in Europe in 2014. About one-third of the $18.5bn Mr Ackman manages sits in this listed unit.
Unlike investors in Mr Ackman’s hedge fund, Pershing Square Holdings shareholders who want to cash out must do so by selling their shares on Euronext, rather than withdrawing from the fund. “Permanent capital is the best protection,” he says. “I wanted to make it both compelling and material.”
Listed funds have also been raised by Third Point, the US hedge fund manager founded by Daniel Loeb, and (twice) by London-based Brevan Howard. Mr Loeb and David Einhorn’s Greenlight Capital are also among the hedge funds to have set up reinsurance companies in recent years. These bring in billions of dollars in additional money to invest, thanks to the companies’ capital reserves and insurance premiums, and have favourable tax treatment. Apollo, the private equity group founded by Leon Black, has nurtured an insurance group that has added tens of billions of dollars in permanent capital.
Other stock market listed vehicles could include special purpose acquisition companies — also known as shell companies — which raise capital for a future deal, real estate investment trusts, business development corporations and holding companies.
Advocates in the industry believe permanent capital vehicles hold the answer to another long-running frustration of alternative asset managers: the stock market’s refusal to value their businesses as highly as traditional fund management companies.
Public market investors dislike the volatility of alternative asset managers’ fee income, which is vulnerable to client redemptions and heavily reliant on unpredictable performance fees. Since permanent capital vehicles pay their managers’ fees in perpetuity, running them should be more valuable, according to the theory.
“These vehicles are likely to be a meaningful alternative,” says Marco Masotti, a lawyer with Paul, Weiss, Rifkind, Wharton & Garrison in New York, who helps many of the biggest firms to structure them. “There is no ticking clock of a finite life and there is always a readily available pool of capital.”
Mike Vranos, founder of mortgage specialist hedge fund Ellington Management, says the ability to pick from a variety of capital-raising structures increases a firm’s flexibility and there is a “game theoretical aspect” to picking the right framework.
Since the crisis, Ellington has created and listed two permanent capital vehicles, a Reit and a $670m specialty finance company called Ellington Financial, which buys mortgage-backed securities and also owns part of a mortgage lender. “Permanent capital allows you to go into less liquid assets and even operating businesses, which require patient money,” Mr Vranos said.
Permanent capital vehicles typically must be listed on a stock market to allow investors the option of getting out — and that comes with disclosure requirements that would be anathema to hedge fund managers a decade ago. “It is a higher bar because there is a lot of scrutiny on the manager, a lot of issues around infrastructure and compliance, so you have to be up for it,” he says.
Those hurdles seem smaller, however, now that many, such as Blackstone and KKR in the private equity industry and Och-Ziff from the hedge fund world, have floated their own management companies on the stock market. Since the Dodd-Frank reforms of 2010, US hedge funds have been required to register with the Securities and Exchange Commission, and hedge fund managers now get most of their money from pension funds, which have high due diligence requirements.
Blackstone and Apollo have been among the private equity pioneers which have transformed their businesses into diversified investment management companies spanning private equity, hedge funds, asset allocation strategies and numerous other products for clients, including permanent capital vehicles. The expansion of their model comes amid concern that competition has cut the potential returns from the traditional 10-year private equity fund.
Some large firms, including Blackstone and Carlyle, are trying to lure their investors into funds with a lifetime of up to 20 years as a halfway house between the traditional 10-year fund and permanent capital. Investors are divided about the virtues of such a long lock-up.
Hanging on to lucrative investments longer is one of the more powerful arguments of proponents of permanent capital models.
Just ask Wes Edens about mobile phone towers. His New York-based private equity and hedge funds firm, Fortress, assembled a national portfolio of towers after the dotcom bust but had to sell the business in 2008. “Had we owned that in a permanent capital vehicle we would still own it today,” he says.
Fortress has been expanding its range of businesses since the credit crisis, and now has a diverse set of six listed or soon-to-be-listed vehicles that specialise in areas including healthcare, mortgage services and US newspapers.
As well as Mr Buffett’s, the business models Mr Edens uses for comparison are those of Teekay, a Canadian energy investor, and Carl Icahn, the controversial corporate raider. Mr Icahn runs a family-only hedge fund but also has an $11.4bn listed vehicle called Icahn Enterprises, whose businesses span railcars, metal recycling and textiles.
Mr Edens said: “Comparing yourself to Warren Buffett, good. Comparing yourself to Carl Icahn, not bad exactly, but Carl is Carl. However, if you look at what he has done in the permanent capital vehicle, it has been really productive.”
Not all the experiments in permanent capital have been a success. KKR listed a vehicle on the Euronext exchange, but it was absorbed into KKR’s New York-listed stock after trading at a discount.
And even Mr Ackman, whose investments were up more than 40 per cent in 2014, has not received the stock market welcome he hoped for. Despite his prediction that Pershing Square Holdings will one day trade at a Berkshire Hathaway-like premium, it has traded stubbornly at a discount, suggesting investors want to build in a margin of error in case performance slips.
The early evidence suggests potential shareholders will be cautious about these options for tapping the expertise of hedge fund and private equity managers. The capital may be permanent, but history suggests that investing success may not be.
Exit strategy: After making a profit, time to ‘harvest’ Alibaba?
Three years before Alibaba set a record with its $25bn IPO, Silver Lake Partners began building a stake in the Chinese ecommerce giant.
Silver Lake, a private equity firm, invested $450m at a blended cost of $14 a share. It was a good price: Alibaba went public in September at $68 a share, after which Silver Lake sold 7 per cent of its holdings and distributed the proceeds to investors, according to confidential letters to them.
Alibaba reached $88 by the end of the third quarter, giving Silver Lake’s remaining stake a value of $2.8bn. Those spectacular results have given its Silver Lake Partners III fund — which made its first investment in 2007 — a huge boost.
But when should Silver Lake cash out?
The life cycle of a private equity fund is generally 10 years. Investors expect managers to put their money to work in the first five years and then start to cash out.
The lock-up period for the listed shares for Alibaba’s private equity holders ends in March. One investor says he would like Silver Lake to either distribute the shares to investors or return cash to them sooner rather than later.
This investor was told that Silver Lake has not decided on when it will sell its shares. A general partner such as Silver Lake has total discretion over the timing of an exit. Still, the Silver Lake fund is already in the period in which it would be normal to wind down its holdings. A spokesman declined to comment.
By contrast, General Atlantic, another private equity firm with a stake in Alibaba, has taken a different approach. It has what it calls an evergreen structure, meaning it is not bound to invest over five years and then “harvest” its investments over the following five. It also has much more freedom in timing its exits.
Investors who think Alibaba shares are a good long-term bet might be happy to give their fund managers a little extra freedom.

FT : Allergan takeover saga ended with deal of the year

Allergan takeover saga ended with deal of the year

Boxes of Allergan Inc. Botox cosmetic are arranged for a photograph at a doctor's office in Manhattan Beach, California, U.S., on Tuesday, April 22, 2014. Valeant Pharmaceuticals International Inc. offered to buy Allergan Inc., maker of the Botox wrinkle treatment, in a cash-and-stock deal valued at $45.7 billion in the latest step of the Canadian company’s plan to become one of the world’s largest drugmakers. Photographer: Patrick T. Fallon/Bloomberg©Bloomberg
For the past three decades the great and the good of the pharmaceuticals industry have descended on San Francisco for a week in January. They ostensibly come for JPMorgan’s annual healthcare conference at the historic St Francis hotel, but everyone in the sector knows that the real action takes place in the cocktail bars and restaurants that are dotted around Union Square.
It was here, almost exactly a year ago, that two men met to hatch a plan that would morph into the biggest and most acrimonious takeover battle of 2014. The following account of that battle is based on interviews with people familiar with the matter, as well as court documents and filings.

One of the men was Bill Doyle, a former Johnson & Johnson executive who had recently started working for his old classmate, the billionaire hedge fund manager Bill Ackman. The other was Michael Pearson, chief executive of Valeant Pharmaceuticals, who Mr Doyle knew from their days as management consultants at McKinsey. The pair discussed the merits of forming a novel dealmaking partnership between Mr Ackman’s hedge fund and Valeant.
Under Mr Pearson’s leadership Valeant had become a mergers and acquisitions juggernaut with a voracious appetite for debt-fuelled deals. After buying a company, Mr Pearson extracted higher profits by taking an axe to costs, a strategy that had served his investors well.
Mr Pearson thought teaming up with Mr Ackman, one of the most feared activist investors on Wall Street, could help Valeant snare a company he had been interested in for several years: Allergan, the maker of blockbuster wrinkle treatment Botox.
The San Francisco meeting went so well that Mr Pearson and Mr Ackman met three weeks later and discussed a bid. After that, things moved quickly: the pair agreed on the terms of an alliance and signed a confidentiality agreement. Pershing Square, Mr Ackman’s hedge fund, would quietly amass a large stake in Allergan and then Valeant would pounce. Together they would exert enough pressure to win over other investors.
Around the same time, Mr Pearson invited David Pyott, Allergan’s chief executive, to dinner, but the pair never met. Mr Pearson cancelled after Mr Pyott let it be known through a number of industry analysts that he had no interest in pursuing a transaction with Valeant.
The Big Read: Permanent capital

William "Bill" Ackman, chief executive officer of Pershing Square Capital Group LLC and Canadian Pacific Railway Ltd. board member, attends the Canadian Pacific Railway annual shareholders meeting in Toronto, Ontario, Canada, on Wednesday, May 1, 2013. Ackman resigned from J.C. Penney Co.’s board on Aug. 13, 2013, ending his public fight to push Chief Executive Officer Mike Ullman out after the CEO got support from investors including Soros Fund Management LLC. Photographer: Norm Betts/Bloomberg *** Local Caption *** Bill Ackman
Private equity and hedge funds seek new holy grail: a never-ending supply of money to invest
Continue reading
It is hard to overstate the disdain Mr Pyott felt towards Valeant and its chief executive. He thought the company’s strategy of slashing spending on research and development would destroy shareholder value, and his legacy at Allergan.
Mr Pyott joined the company in 1998 and transformed it from a niche maker of eyecare products into one of the most admired companies in the industry. Born in England to Scottish parents, his accent has developed a hint of transatlantic drawl, but his soft-spoken, polite style can seem at odds with the cut and thrust of the US boardroom.
During March and April, Mr Ackman amassed a stake of almost 10 per cent in Allergan. Then, on April 22, Valeant and Pershing Square went public, announcing their $47.5bn hostile takeover offer at a press conference that lasted almost four hours.
The seven-month takeover battle that followed was brutal. Mr Pearson and Mr Ackman launched a bitter proxy war to eject Allergan’s directors and replace them with a board more amenable to a takeover.
Allergan responded by attacking Valeant’s business model and trying to block the attempt to unseat its directors in the courts. In the middle of June, the Botox-maker went so far as to publish a cache of private emails from Morgan Stanley. The investment bank had tried, and failed, to win a place on Allergan’s advisory team, but ended up working for the other side.

Before Morgan Stanley switched teams it sent a series of emails to Allergan that were highly critical of Valeant. In one, Rob Kindler, the banker leading Valeant’s pursuit, was quoted as describing the company’s business model as a “house of cards”.
Meanwhile, Allergan came close to buying Salix, a gastrointestinal drugmaker that was worth about $10bn, in September. The deal could have made Allergan too large for Valeant to swallow, but it called talks off at the eleventh hour after uncovering an accounting scandal that would claim Salix’s finance chief.
Valeant raised its offer twice and twice it was rejected. On a Sunday in early October, Mr Ackman and Mr Pearson met at Teterboro airport in New Jersey, a favourite for executives flying their private jets in and out of New York. They discussed raising the offer for a third time. Mr Ackman was keen, but his partner wanted to wait.
However, the following Tuesday, the news they were considering sweetening their bid leaked, much to the chagrin of Mr Pearson and his bankers. Two weeks later, the Financial Times asked Mr Pearson if he and Mr Ackman had fallen out over strategy. “Do we always agree on every tactic? No,” he replied.
Despite growing tensions in the Valeant camp, a deal appeared to be within reach. If Valeant could secure a majority of shareholder votes at a special meeting in December, it would be able to eject Allergan’s directors and push for a transaction.
The maths did not look good for Allergan. Some of its biggest investors wanted to sell to Valeant, as did a number of hedge funds that had bought shares in anticipation of a deal. Its only real hope was that a Californian judge would prevent Mr Ackman from voting his 10 per cent stake.
It was around this time that Allergan adopted, in the words of one of its advisers, an “anyone but Valeant” strategy. Back in August, Actavis, an Ireland-based drugmaker that was growing at a blistering pace, had signalled its interest in buying the company. Mr Pyott was friendly with its recently installed chief executive Brent Saunders — the pair had dined together over the years — but the discussions never really took off. At the end of October, the talks resumed with a fresh sense of urgency.
On November 4, came the moment that everyone had been waiting for: the Californian court ruled that Mr Ackman could vote his stake at the December meeting. Allergan would almost certainly lose and be forced into the arms of Valeant.
The following day Allergan signed a confidentiality agreement with Actavis and the pair began rushing to complete a deal. Its days as an independent company were over. Mr Pyott and Mr Saunders agreed that they had to do the deal at a price that would make it impossible for Valeant to come back with a counter-offer.
Even so, the $219-a-share agreed deal, which valued the company at $66bn, stunned observers when it was announced on November 17. The highest bid Valeant had made was $179 a share. It took less than an hour for Mr Pearson to rule himself out of the race.
In the words of one of his advisers, it was a “bittersweet” moment for Mr Pyott, who stands to make hundreds of millions of dollars from his share options when the deal is completed. As for Mr Ackman and Mr Pearson, neither will say whether they have any plans to work together in the future.
Allergan, Valeant, Actavis and Pershing Square declined to comment.

Key dates

Apr 21 Pershing Square discloses 9.7 per cent stake in Allergan
Apr 22 Valeant and Pershing Square announce $47.5bn bid for Allergan
May 3 Pershing proposes to eject six of Allergan’s directors
Aug 1 Allergan sues Pershing and Valeant, alleging insider trading
Nov 4 Californian judge rules Pershing can vote its shares at special meeting
Nov 5 Allergan signs confidentiality agreement with Actavis
Nov 17 Actavis and Allergan announce agreed deal worth $66bn

>>> Alisarda attracts interest of Qatar Investment Authority

Alisarda attracts interest of Qatar Investment Authority
Alisarda (formerly Meridiana), the Italian airline owned by the Aga Khan, has attracted the interest of sovereign wealth fund the Qatar Investment Authority , Italian-language daily La Stampa reported. The unsourced report said that the QIA is interested in taking a 20% stake in the airline.

The report cited an Alisarda spokesperson as noting that it had not yet received any manifestation of interest from the QIA.
La Stampa

>> Aer Lingus shares gain on talk of increased bid of up to EUR 2.60 per share f

Aer Lingus shares gain on talk of increased bid of up to EUR 2.60 per share from IAG 

Aer Lingus’ share price gained yesterday, 2 January on talk that International Consolidated Airlines Group (IAG) had increased its takeover offer for the listed Irish airline, The Irish Independent reported. The newspaper mentioned talk that IAG may have told Aer Lingus that it is now willing to offer between EUR 2.40 (USD 2.88) per share and EUR 2.60 per share, but did not cite a source for the speculation.

It is understood that IAG’s initial bid approach for Aer Lingus, prior to Christmas, involved an EUR 2.20 per share indicative bid, the item said. The Aer Lingus board rejected the offer, the article added.

IAG refused to comment yesterday evening, the item said.

The Irish government holds a 25.1% stake in Aer Lingus and would be looking for an offer higher than EUR 2.20 per share in the event that it thinks about selling the stake, the report added.

Ryanair, a listed Irish budget airline, holds a stake just short of 30% in Aer Lingus, while the Abu Dhabi-based airline Etihad holds a stake of slightly less than 5%, the article noted.

Aer Lingus share price gained more than 3% inside of an hour after the close of stock market trading in Dublin yesterday, according to the report. Aer Lingus shares closed EUR 0.089 up at EUR 2.295, giving the airline a market capitalisation of EUR 1.22bn.
Irish Independent

FT : Economists sceptical ECB bond-buying would revive eurozone

Economists sceptical ECB bond-buying would revive eurozone
Any effort by the European Central Bank to launch a massive quantitative easing programme this year would fail to revive the eurozone economy, according to economists polled in a Financial Times survey.
The FT survey of 32 eurozone economists, mainly working in the financial sector, conducted in mid-December, found most expected the ECB to launch QE in 2015 — catching up with the world’s other main central banks that have all bought large quantities of sovereign debt since the last financial crisis.

Twenty-six economists forecast the central bank would start purchasing government bonds this year, while five thought it would not. One did not respond to the question.
A stuttering recovery and a worrying drop in inflation have raised fears of another financial crisis in the currency bloc and put pressure on policy makers to cast aside powerful opposition from Germany and begin purchasing sovereign debt.
ECB president Mario Draghi last week gave his strongest signal yet that the central bank would extend its asset purchases to include sovereign debt in the next few months. A decision could come as early as the next governing council meeting on January 22.
But most of the FT poll’s respondents expected growth and inflation to remain weak even with quantitative easing. “[QE] will help lift inflation expectations and reduce the euro, but [it’s] not a total game changer,” said Dario Perkins, economist at Lombard Street Research.
Jörg Krämer of Commerzbank said QE would lower the yield on government bonds and “help the finance ministries of highly indebted countries such as Italy, and its banks”. But he added that QE would not change low growth and inflation levels and would “only fuel asset prices”.
While several respondents said government bond-buying was likely to help fight the threat of deflation and lower yields on debt issued by weaker sovereigns, most economists agreed that growth would remain lacklustre unless governments backed the ECB’s efforts.
“QE is not a panacea for the euro-area,” said Carsten Brzeski of ING DiBa, a bank. He suggested that the biggest impact from any QE would come “if governments were at the same time allowed to start a deficit-financed investment programme. [It’s] doubtful [that] will ever happen in the euro area.”
Some said a larger package stood more chance of success. “If it is big enough, it will have some effect on the economy, if only to bring the euro down,” said Jonathan Loynes of research group Capital Economics. “It’s worth a try.”

Of the economists who put a number on the size of the purchases, the most popular guess was €500bn, although some put the figure as high as €1tn and others as low as €250bn. Some also expected the ECB to start buying corporate debt alongside sovereign bonds.
Eurozone inflation dropped to 0.3 per cent in November, less than a fifth of the ECB’s target of just below 2 per cent. Inflation is likely to have fallen again in December on the back of the sharp drop in oil prices.
Mr Draghi and most of the governing council backed a new development in ECB policy in December, saying the expansion of the central bank’s balance sheet from €2tn towards the €3tn mark was now expected.
However, six policy makers objected to the December decision, underlining the extent of divisions over quantitative easing. Jens Weidmann, the Bundesbank’s president, was among the dissenters, and while Berlin is not expected publicly to oppose the policy, resistance within Germany remains fierce.
Many economists think it is impossible for the ECB to hit the €3tn level by confining its purchases to the assets it buys at the moment: covered bonds and asset-backed securities. “The ECB will purchase sovereign debt in 2015, mostly for want of anything else to buy,” said Lorcan Roche Kelly of Agenda Research.
Economists back Mario Draghi’s call for eurozone action
The European Central Bank in Frankfurt
Economists have backed president Mario Draghi’s calls for politicians to do more to support the European Central Bank’s efforts to rescue the eurozone from stagnation, but they remain sceptical that lawmakers in Berlin will listen. In a Financial Times poll of eurozone economists conducted in mid-December, a majority of respondents also viewed the EU’s tough budget rules as not fit for purpose.
Continue reading
Twenty-six respondents to the FT’s poll thought the size of the ECB’s balance sheet would lie somewhere between €2tn and €3tn by the end of 2015. Two thought the ECB would be able to hit €3tn over the next 12 months, while four thought the balance sheet would fall below €2tn.
Some respondents thought resistance within the council could affect the programme, with others suggesting the ECB would ensure national central banks bore the risk from buying their governments’ bonds.
“The ECB will most probably have to limit sovereign purchases to investment grade sovereigns,” said Hetal Mehta of Legal & General Investment Management, an insurer.
“The purchases will consist of nationally-weighted sovereign [debt purchases]. I think that [credit] risk will probably [be] decentralised at the national level via some mechanism,” said Lucrezia Reichlin, a professor at London Business School and co-founder of data firm NowCasting.
Richard Barwell of Royal Bank of Scotland said: “There may be compromises in the design to get as many people on board as possible, but I expect a sufficiently strong signal that the ECB is determined to do what it takes to preserve price stability and that’s what counts in the end.”
Kit Juckes of Société Générale said buying European Investment Bank bonds to spur investment spending was a “more appealing” way for the ECB to spend its cash.
Harald Benink, a professor at Tilburg University, agreed. “Our proposal of buying bonds . . . issued by the EIB is likely to be more acceptable to the Bundesbank since it is violating to a lesser extent monetary financing rules as contained in the [EU] Treaty”, he said.

FT : Big pharma waits decision on cancer drugs

Big pharma waits decision on cancer drugs

A scientist prepares protein samples for analysis in a lab at the Institute of Cancer Research in Sutton©Reuters
Tensions are rising between pharmaceutical companies and the UK government, as the industry braces for a decision on which drugs will be axed from a special fund for expensive cancer therapies.
NHS England is due to announce the results of a review of the cost-effectiveness of more than 40 medicines currently paid for by the Cancer Drugs Fund.
The expected decision to cut the number of cancer treatments available to NHS patients in England will intensify debate over access to medicines, as the government battles to close a forecast £30bn health funding gap by 2020-21.
Pharmaceutical companies say patients risk being denied the latest treatment because of financial pressure while critics accuse the industry of overcharging for medicines that offer only marginal benefits over existing products.
These arguments have come to the fore in the increasingly rancorous dispute over the Cancer Drugs Fund, which was set up in 2010 to provide extra funding for medicines deemed too expensive under the usual formula for judging value for money in the NHS.
Many medical professionals and academics object to the fund because it provides special treatment for cancer patients only and because it overrides the recommendations of the National Institute for Health and Care Excellence (Nice), the body that assess the cost-effectiveness of drugs.
This view appears to have been gaining ground in government as the growing cost of the fund has focused ministers’ minds on the budgetary implications of a policy that has been described as a “blank cheque” for cancer drugs.
In August, NHS England announced a 40 per cent increase in the fund’s annual budget to £280m and the government has since admitted it is already on course to “exceed” this increased figure in 2014-15.
In an attempt to bring costs under control, advisers to NHS England met last month to re-evaluate which drugs should be covered, with those demonstrating the weakest cost-effectiveness at risk of exclusion.
NHS England says the changes will put the fund “on a much firmer footing . . . as it faces increasing demand and growing financial pressure” while “encouraging pricing that delivers value for money for patients and the public”.
The Association of the British Pharmaceutical Industry has warned that the measures “threaten to take the UK back to a time of clear rationing of cancer medicines”.
However, big pharma is far from unanimous in its support for the fund, which disproportionately favours companies such as Roche, Johnson & Johnson and Novartis which are strong in cancer drugs.
Stephen Whitehead, chief executive of the ABPI, said the best outcome would be a reformed Nice with more flexibility to recommend expensive cancer medicines.
Nice judges medicines based on their cost per “quality-adjusted life year” (QALY) — a formula designed to measure the price of a drug versus the health benefit it delivers. The institute has generally considered £30,000-per-QALY as its upper threshold for cost-effectiveness.
This is far below the price of some of the most advanced cancer drugs.
One high-profile example is Roche’s Kadcyla breast cancer medicine, which was shown in clinical trials to extend life by an average six months compared with existing treatments, at a list price of £90,000 per patient.
The drug was rejected by Nice last August but is available through the Cancer Drugs Fund.
Critics say the ability for companies to sell their cancer medicines through the fund in spite of rejection by Nice meant there was no pressure to cut prices until the recent overhaul. Kadcyla is among the 40 products under review by NHS England.
The Cancer Drugs Fund is due to expire in 2016 but Labour last month said it would set up its own version if it wins the general election in May — demonstrating the public pressure on all parties to fund treatment for cancer.